[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627317":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":69,"collaborators":71,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":25,"enrollmentInfo":85,"targetDuration":25,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":99,"whyStopped":25,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sodium tablets first","EXPERIMENTAL","Participants will be randomized to receive sodium tablets for weeks 13-17, no tablets for a washout period during weeks 18-19, then placebo tablets for weeks 20-24.",[13,14],"Drug: Sodium chloride tablets","Other: Placebo Tablets",{"label":16,"type":10,"description":17,"interventionNames":18},"Placebo tablets first","Participants will be randomized to receive placebo tablets for weeks 13-17, no tablets for a washout period during weeks 18-19, then sodium tablets for weeks 20-24.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Sodium chloride tablets","During the 5-week long sodium tablet intervention period, participants will receive five 1 g sodium chloride tablets each morning and four 1 g sodium chloride tablets each evening. Each sodium chloride tablet will contain 0.394 g or 17 mmol of sodium.",[16,9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo Tablets","During the 5-week long placebo period, participants will receive five placebo tablets each morning and four placebo tablets each evening",[16,9],[31],{"name":32,"affiliation":5,"role":33},"Katrina Abuabara, MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Alicia Hamblin, BS","CONTACT","925-549-7889","Alicia.Hamblin@ucsf.edu",{"name":32,"role":37,"phone":41,"phoneExt":25,"email":42},"415-514-9769","katrina.abuabara@ucsf.edu",[44,60],{"facility":45,"status":25,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"San Francisco VA Medical Center","San Francisco","California","94115","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-122.41942,37.77493,{"lat":55,"lon":54},[58,59],{"name":36,"role":37,"phone":25,"phoneExt":25,"email":39},{"name":32,"role":37,"phone":41,"phoneExt":25,"email":42},{"facility":61,"status":25,"city":46,"state":47,"zip":62,"country":49,"countryCode":50,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"UCSF Mt Zion Campus","94511",{"type":52,"coordinates":64},[54,55],{"lat":55,"lon":54},[67,68],{"name":36,"role":37,"phone":25,"phoneExt":25,"email":39},{"name":32,"role":37,"phone":41,"phoneExt":25,"email":42},{"type":70,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[72],{"name":73,"class":74},"United States Department of Defense","FED","100627317","phase-4-the-impact-of-dietary-salt-on-the-severity-of-eczema-100627317",false,"NCT07447063","The Impact of Dietary Salt on the Severity of Eczema","iDOSE","Inclusion Criteria:\n\n* Participants ages 18 years\n* Willing and able to undergo non-contrast MRI.\n\nExclusion Criteria:\n\n* Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants)\n* A cardiac event in the past 6 months\n* Impaired function of the liver or kidney (glomerular filtration rate \\\u003C60 mL\u002Fmin)\n* Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors)\n* Antibiotic or immunomodulatory medications within the last month\n* Contraindications to sodium tablets\n\n(Topical medications used exclusively on the head\u002Fneck or hands\u002Ffeet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.)",true,"ALL","18 Years",{"count":86,"type":87},40,"ESTIMATED","INTERVENTIONAL",[90],"PHASE4","The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are:\n\n* Does a low-sodium diet improve eczema severity?\n* How does a low-sodium diet impact skin sodium concentration?\n* Is skin sodium concentration associated with eczema severity?\n\nResearchers will ask all participant to follow a low-sodium diet, then compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake.\n\nParticipants will:\n\n* Follow a low-salt diet for the duration of the 24-week study\n* Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa\n* Complete up to 4 virtual check-in visits\n* Visit the clinic 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI",[93,94],"Eczema","Atopic Dermatitis",[96,97,98],"sodium","salt","diet","NOT_YET_RECRUITING","2026-06-05",{"date":102,"type":103},"2026-06-09","ACTUAL",{"date":105,"type":87},"2026-06-22",{"date":107,"type":87},"2028-05-05",{"name":5,"class":6},2]